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Abstract
Background: Williams-Beuren syndrome (WBS; OMIM 194050) is caused by a hemizygous contiguous gene
microdeletion at 7q11.23. Supravalvular aortic stenosis (SVAS), mental retardation, and overfriendliness comprise
typical symptoms of WBS. Although fluorescence in situ hybridization (FISH) is considered the gold standard
technique, the microsatellite DNA markers and multiplex ligation-dependent probe amplification (MLPA) could be
used for to confirm the diagnosis of WBS.
Results: We have evaluated a total cohort of 88 patients with a suspicion clinical diagnosis of WBS using a
collection of five markers (D7S1870, D7S489, D7S613, D7S2476, and D7S489_A) and a commercial MLPA kit (P029).
The microdeletion was present in 64 (72.7%) patients and absent in 24 (27.3%) patients. The parental origin of
deletion was maternal in 36 of 64 patients (56.3%) paternal in 28 of 64 patients (43.7%). The deletion size was 1.55
Mb in 57 of 64 patients (89.1%) and 1.84 Mb in 7 of 64 patients (10.9%). The results were concordant using both
techniques, except for four patients whose microsatellite markers were uninformative. There were no clinical
differences in relation to either the size or parental origin of the deletion.
Conclusion: MLPA was considered a faster and more economical method in a single assay, whereas the
microsatellite markers could determine both the size and parental origin of the deletion in WBS. The microsatellite
marker and MLPA techniques are effective in deletion detection in WBS, and both methods provide a useful
diagnostic strategy mainly for developing countries.
Background
Williams-Beuren syndrome (WBS; OMIM 194050) is a
neurodevelopmental disorder described independently
[1,2] as a syndrome involving facial appearance charac-
teristics, supravalvular aortic stenosis (SVAS) and men-
tal retardation. In fact, WBS presents a wide collection
of symptoms affecting blood vessels, growth, intelli-
gence, and behavior. Children with this condition have
distinctive facial features, a hoarse voice associated with
growth, mental retardation and an overfriendly personal-
ity; hyperacusis, infantile hypercalcemia, prematurely
wrinkled skin are also common symptoms [3].
WBS is generally sporadic with frequency of approxi-
mately 1 in 7,500 live births with no ethnic or sex pre-
ference, although familial cases have been reported with
apparent autosomal dominant inheritance [4,5]. Despite
the consistency of the overall clinical features, the broad
spectrum of anomalies and phenotypic variability fre-
quently lead to a significant difference in the number of
patients diagnosed [6].
WBS is caused by a hemizygous contiguous gene
microdeletion of the WBS critical region on chromo-
some 7 at position 7q11.23. The most common deletion
is found in 90% to 95% of WBS patients and spans a
genomic region of approximately 1.55 Mb. It is the
result of mispairing between the centromeric and medial
LCR (Low copy repeats) blocks B (Bcen and Bmid) [7].
In 5% to 10% of cases, the breakpoints are within the
centromeric and medial LCR blocks A (Acen and Amid)
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any medium, provided the original work is properly cited.and lead to an ~1.84-Mb deletion [8]. Atypical (approxi-
mately 0.2 Mb to ~2.5 Mb) deletions may be the leading
cause of the substantial phenotypic variability among
WBS patients [9].
Duplication of the WBS region occurs at half the fre-
quency of deletions with less distinctive and somehow
opposite clinical features, such as deficits of social inter-
action and an autistic-like phenotype [10,11].
Confirmation of clinical suspicion is essential for clini-
cal monitoring of the patient and genetic counseling of
the family. Although fluorescence in situ hybridization
(FISH) is widely used and considered the gold standard
for WBS molecular diagnosis, the use of microsatellite
DNA markers has also been widely used and is consid-
ered highly informative and easily performed [12,13].
Multiplex ligation-dependent probe amplification
(MLPA) has been introduced into DNA diagnostic
laboratories for the detection of deletions and/or dupli-
cations in several disease genes [14]. MLPA kit for
WBS, makes possible a more precise mapping of the
deletion in the critical region, compared with the FISH
[15]. In this study, the results obtained with microsatel-
lite markers were compared with those obtained with
MLPA.
It can be argued that both techniques, together, are
extremely valuable tools for the diagnosis of the WBS
patients and that the implementation of both methods
should be considered.
Results
A total of 88 patients with the suspicion of a clinical
diagnosis of WBS were tested. The five markers
(D7S1870, D7S489, D7S613, D7S2476 and D7S489A)
were informative in 84 patients and not informative in 4
patients. The most informative marker was D7S1870
(78.4% of patients), followed by D7S613 (68.2% of
patients), D7S489 (65.9% of patients) and D7S2476
(57.9% of patients). The microdeletion was present in 64
(72.7%) patients and absent in 24 (27.3%) patients.
The observed deletion size was 1.55 Mb in 57 of 64
patients (89.1%) and 1.84 Mb in 7 of 64 patients
(10.9%). For the parental origin, the deletion was mater-
nal in 36 of 64 patients (56.3%) and paternal in 28 of 64
patients (43.7%).
Using the MLPA kit (P029), the results were concor-
dant with the microsatellite marker analysis in 84
patients and on 4 cases the deletion was only detected
by MLPA (Figure 1). FISH was performed in all patients
and the results were concordant with those found by
microsatellites and MLPA.
The microsatellite markers used in the present study,
are located in different regions in comparison with the
probes in the P029 kit for WBS (Figure 2). Except the
D7S489 marker and the FZD9 probe from MLPA P029
kit that are in the same position (Figure 3). Considering
both techniques, there was no clinical difference in rela-
tion to either the size of deletion or the parental origin
of deletion.
Discussion
Microsatellite DNA markers and MLPA have been con-
sidered highly informative and easily manageable for
diagnostic confirmation of WBS.
In our study, five microsatellite markers (D7S1870,
D7S489, D7S613, D7S2476, and D7S489A) were infor-
mative, except in four cases.
Figure 1 Genotyping by MLPA technique (SALSA kit P029)
using the software GeneMarker
® for analysis. Hemizygous
contiguous gene microdeletion, can be visualized by probes 21 to
32. With the presence one copy these genes in the WBS critical
region, 7q11.23.
Figure 2 Representation of the 7q11.23 region and the
location of the probes from SALSA kit P029 and the markers
tested. The patients 54 and 55 were represented in the figure to
illustrate the localization of the genes in the region 7q11.23 and the
size of the deletion. Neg. Negative; Pos. Positive and Un.
Uninformative.
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microcephaly, and cardiovascular anomalies were absent,
but not in one patient that presented mitral and tricus-
pid regurgitation and hiperacusis.
The D7S1870 microsatellite marker showed the high-
est power of detection, able to identify 78.4% of the
cases by itself, which confirmed the results from pre-
vious studies [8,16-19].
Two best markers (D7S1870 and D7S613) in our
study were able to detect the deletion in 93.2% of cases
when used together. When the D7S613 and D7S489
markers were included, informative detection increased
to almost 95%.
The microsatellite marker D7S489A was effective in
the analysis of deletion size. The 1.55-Mb deletion was
found in 57 of 64 (89.1%) patients, and the 1.84-Mb
d e l e t i o nw a sf o u n di n7o f6 4p a t i e n t s( 1 0 . 9 % ) ;t h e s e
observed percentages are similar to those found in other
studies in the literature [8].
Using markers to identify the parental origin, we
found no significant difference between the frequencies
of maternal and paternal deletions (56.3% and 43.7%,
respectively), and the literature is concordant with our
findings [12,13,17,19].
There was also no relationship between clinical fea-
tures with the size of the deletion and with the parental
origin.
Since the MLPA technique was developed [14], it has
been tested as a diagnostic method in several diseases
involving chromosomal disorders. In this study, we used
the MLPA kit (P029) to observe the microdeletion in 64
(72.7%) patients and find it was absent in 24 (27.3%)
patients.
We find four discrepant results comparing the micro-
satellite markers and the MLPA method in the detection
of deletions in the WBS critical region. In these patients
where the microsatellite markers are uninformative,
detection of the deletion can be confirmed using the
MLPA technique. These patients present a phenotypic
variability that often leads to diagnostic difficulties and
the confirmation of results only was possible using
MLPA technique.
The microsatellite markers were efficient in deletion
detection for WBS when compared to the MLPA. They
allowed for the detection of deletions larger than 1.55
MB and for detection of the parental origin of the
deletion.
FISH is widely used and considered the gold standard
for WBS molecular diagnosis, however, FISH is labor-
intensive, time-consuming, and it does not allow the
detection of the exact size of the deletion [20].
The cost of the microsatellite marker technique has
greatly decreased, and it can be deployed in molecular
biology laboratories that have basic equipment for con-
ventional PCR reactions and a vertical electrophoresis
system.
The most important advantages of the MLPA are its
relative simplicity, low cost, rapid turnaround (2 days),
ease of multiplexing to permit high confidence in the
results, high accuracy of copy number estimation, and
the potential for combination of copy number analysis
with other applications, such as methylation detection
or SNP genotyping [21].
The accuracy of both diagnostic tests is well recog-
nized to be susceptible to technical problems and clini-
cal heterogeneity. In our study, FISH, markers and
MLPA presented higher sensitivity (99.8%), similar to
others studies [22] and microsatellites markers presents
lower specificity compared to FISH and MLPA (93%).
Real-time quantitative polymerase chain reaction tech-
nique (QPCR) and array-based comparative genomic
hybridisation (array-CGH) are also being used for the
molecular diagnosis of WBS.
QPCR is considered a robust methodology, with easy
interpretation, and simple to set up [23,24]. Conversely,
to perform this technique we need sophisticated
Figure 3 Comparison between the results obtained by microsatellite markers and MLPA. A total of 88 patients participated of the study
and numbered 1 to 107. The correspondent probe to gene FZD9 is localized in the same region that D7S489 microsatellite marker.
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differently from MLPA, where the simultaneous hybridi-
zation of more than 40 different probes can be used in
one single reaction.
Recently, array-CGH has also been proved also to be a
powerful and promising method to detect microdele-
tions and to identify novel cytogenetic abnormalities
[25]. However, the resolution of array-CGH can vary
depending on the format and design of the array [26].
Additionally, this method is relatively difficult and
costly, and it requires a different setup as far as instru-
mentation is concerned [25].
Economic models are important to help health profes-
sionals to take decisions based on available strategies.
The molecular tests available together with socio eco-
nomic characteristics of the country is fundamental
when a new strategy is considered to be taken, especially
in developing countries where resources are limited [27].
Conclusions
The diagnosis of WBS based on clinical assessments
may be difficult because of the great variability of its
manifestations. Laboratory tests to detect the microdele-
tions in 7q11.23 are essential to confirm the clinical
diagnosis of WBS.
In summary, the microsatellite marker and MLPA
techniques are effective in deletion detection in WBS,
and both methods improve complete molecular cover-
age in screening of the critical region mainly for devel-
oping countries.
Methods
Subjects
A total cohort of 88 patients with a clinical diagnosis of
WBS (56 boys and 32 girls) were followed through clini-
cal evaluation by geneticists of the Unit of Clinical
Genetics - Instituto da Criança, Hospital das Clínicas -
Universidade de São Paulo (ICr-HCFMUSP), Brazil. The
inclusion criteria were dysmorphic facial features sug-
gestive of WBS and the presence of cardiovascular dis-
orders, mainly SVAS.
The study was approved by the Institutional Review
Board - Ethics Committee for Analysis of Research Pro-
jects HCFMUSP/Cappesq - and written consent was
obtained from all participants.
Among the 88 patients, DNA from both parents was
obtained in 80 cases; in 8 cases, the molecular analysis
was performed only with maternal DNA. Most of
patients had normal GTG band karyotype and FISH was
previously had been done in 24 patients.
The molecular study was performed in Laboratory of
Genomic Pediatrics - LIM 36 - (Icr -HCFMUSP). DNA
was isolated from peripheral blood lymphocytes using a
salt precipitation technique [28].
Microsatellite markers
The five microsatellites markers used included D7S1870,
D7S489, D7S613 and D7S2476 inside the common 1.55-
Mb deletion and D7S489A to distinguish deletions of
1.84 Mb. PCR reactions were carried out according to
Dutra et al. (2011) [13].
Patient genotypes were compared with those of their
parents. Deletions were diagnosed as maternal when the
proband presented with gel bands representing the alle-
lic marker inherited only from the father. When by
chance both parents have the same alleles, the monoal-
lelic inheritance of the corresponding microsatellite
marker by the proband indicated an uninformative
result.
W ef i r s tu s e dat w o - s t e pa l g o r i t h mt oi d e n t i f yt h e
most common 1.55-Mb deletion. We then tested the
D7S489A marker either to identify the larger 1.84-Mb
deletion (in those patients in which a deletion of at least
one marker was detected in the first step) or to confirm
the lack of a deletion.
MLPA
The MLPA (SALSA kit P029 - MRC-Holland, Amster-
dam, The Netherlands) containing probes for eight
genes from the WBS critical region (FKBP6, FZD9,
T B L 2 ,S T X 1 A ,E L N ,L I M K 1 ,R F C 2and CYLN2)w e r e
used. The ELN and CYLN2 probes for various exons are
present in the kit. Denaturation, overnight hybridisation,
ligation and PCR were performed according to the man-
ufacturer’s instructions.
MLPA products were separated on a MegaBACE™
1000 (GE Life Sciences, Waltham, USA) using Mega-
BACE ET SIZE Standards ET550-R (GE Life Sciences,
Waltham, USA). The analysis was performed using the
GeneMarker, version 1.6, software (Softgenetics, State
College, PA, USA). The ratio of the probes’ peak heights
was determined by comparing the probes’ peak heights
obtained from patient samples to those obtained from
three normal control samples.
Statistical analysis
Pairwise comparisons between clinical features of WBS
and the presence of deletion, clinical features and dele-
tion size and clinical features and parental origin of
deletion were tested for significance using two-tailed
Fisher’s exact test. A 2 × 2 contingency table was used
to compare clinical features. P analysis was performed
in SPSS 13.0 software and considered statistically signifi-
cant when p ≤ 0.05.
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